Kornimate/medical-research-clean huggingface dataset:
cortisone shots for neck pain

Conditions: Neck Pain; Cervicalgia; Facet Joint Pain

Summary: the purpose of this study is to determine if cortisone shots in the neck are helpful in patients with certain mri findings. additionally, the investigators hope to learn if cervical facet joint steroid injections are beneficial in the subset of patients with mri findings consistent with facet joint synovitis.


Eligibility criteria:
inclusion criteria: * at least 18 years old * patient who will be getting a neck cortisone shot for pain that has been there for at least 4 weeks * a specific mri finding (increased short tau inversion recovery signal) around 1 or more of the joints in the neck exclusion criteria: * those receiving disability, worker's compensation, or are involved in litigation related to their pain. * those unable to read english and complete the assessment instruments. * those unable to attend follow up appointments * the patient is incarcerated. * grade 2 or greater spondylolisthesis at the involved or adjacent segments. * history of prior posterior cervical surgery. anterior cervical surgery is not an exclusion criteria. * progressive motor deficit, and/or clinical signs of myelopathy. * prior neck cortisone shots within the past 6 months. * possible pregnancy or other reason that precludes the use of fluoroscopy. * allergy to contrast media or local anesthetics. * bmi\>35. * systemic inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, lupus). * active infection or treatment of infection with antibiotics within the past 7 days. * chronic widespread pain or somatoform disorder (e.g. fibromyalgia). * addictive behavior, severe clinical depression, or psychotic features.
screening for amyloidosis before aortic valve elective replacement

Conditions: Amyloidosis; Aortic Valve Stenosis

Summary: previous studies detected that up to 15% of patients undergoing aortic valve replacement (avr) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (attr) cardiomyopathy (castano, 2017). the aim of this study is to investigate the effectivity and practicability of a systematic attr-screening in patients undergoing planned avr. moreover, we plan to develop a screening algorithm to detect attr in aortic stenosis (as).

untreated cardiac amyloidosis is accompanied with an impaired prognosis. amyloidosis is often associated with ventricular hypertrophy which leads to severe heart failure and occurs frequently in conjunction with bradycardic or tachycardic malignant arrhythmia. patients with degenerative aortic valve stenosis suffer more frequently from cardiac attr. however, it remains unclear whether the development of aortic stenosis is promoted by attr. due to very similar symptoms (shortness of breath during physical exertion, reduced walking distance) diagnosis of aortic valve stenosis is more often diagnosed in a typical cohort of patients aged between 70-80 years but, in contrast, leads to underdiagnosis of patients with additional cardiac amyloidosis. six to fifteen percent of patients with aortic valve replacement due to degenerative aortic valve stenosis exhibit a cardiac amyloidosis. since cardiac amyloidosis without therapeutic intervention is associated with significantly reduced life expectancy, it can be assumed that these patients will not benefit to the same extent from the avr alone as patients without attr. new therapeutic approaches for patients exhibiting attr lead to a reduction of mortality and hospitalizations. the primary aim of this study is to establish a simple attr screening tool in patients with planned avr in the clinical routine and, furthermore, to compare the clinical course following avr between patients with and without attr.

Eligibility criteria:
inclusion criteria: * age ≥40 years * written informed consent from the patient or of his/her legal guardian * hospitalization for avr due to degenerative aortic valve stenosis exclusion criteria: * hemodynamically unstable patient * severe co-morbidities with an estimated life expectancy of \<1 year

Keywords: cardiac amyloidosis transthyretin amyloidosis attr aortic stenosis screening
long-term follow-up study in subjects who received voretigene neparvovec-rzyl (aav2-hrpe65v2)

Conditions: Inherited Retinal Dystrophy Due to RPE65 Mutations

Summary: multi-site, non-randomized, observational study, for up to 15 years after subretinal aav2-hrpe65v2 administration for each subject. the study is a non-interventional, follow-up study of subjects who participated in previous aav2-hrpe65v2 gene therapy clinical trials.

this is an observational follow-up study of subjects who participated in previous phase 1 and phase 3 clinical trials of aav2-hrpe65v2 gene therapy (voretigene neparvovec-rzyl) to evaluate long term durability and safety for 15 years after subretinal administration.

Eligibility criteria:
inclusion criteria: 1. subjects who participated in prior subretinal aav2-hrpe65v2 gene therapy clinical studies exclusion criteria: 1. subjects who will not consent for study. 2. subjects who the investigators believe are not capable of performing study assessments

Keywords: leber congenital amaurosis, retinitis pigmentosa
comparison of coronally advanced flap and semilunar incision vestibular technique for multiple gingival recessions in maxillary teeth - a randomized controlled trial

Conditions: Gingival Recession, Generalized; Root Coverage

Summary: comparison of coronally advanced flap with semilunar vestibular incision technique for root coverage in patients with multiple gingival recession in maxillary teeth.

the subjects attending the opd department of periodontology, igids and patients will be selected based on inclusion criteria, informed consent to be obtained from the patients, randomization process: 1. patient to be selected for one of the two procedures by simple random sampling (lottery method) 2. baseline value will be recorded by a calibrated examiner other than the operator 3. the procedure is performed by the operator ( primary investigator) 4. post op values to be recorded by the calibrated examiner. patient to be reviewed at 3 and 6 months results will be dicussed

Eligibility criteria:
inclusion criteria: * males and females subjects of 20-50 years. * patients with multiple gingival recession (2-4 teeth) of class i \& ii in maxillary teeth. * patients with well aligned teeth exclusion criteria: * patients with class iii \&iv gingival recession in maxillary teeth * recession in relation to molars * patients with systemic diseases * medically compromised patients * patient with history of smoking * patients with erosion and root caries
audiological assessment of recovered covid 19 subjects.

Conditions: Covid 19

Summary: to assess the audiological profile in recovered covid 19 subjects in comparison with control group.

the outbreak of novel severe acute respiratory syndrome corona virus type 2 (nsars-cov-2) infection in wuhan, china in december 2019 has had impact on the world, resulting in over 2.2 million deaths globally the world envisioned sufferings of high proportions of losses in terms of health,finances and importantly, life. the common symptoms including fever, cough, fatigue and gastrointestinal disorders have been well documented. sensorineural hearing loss has been more commonly implicated in these patients although a few have exhibited conductive hearing loss. theviral upper respiratory tract infections have linked to new cases of otitis media. although there is some controversy regarding the significance of viral species, but the human corona virus has been isolated from middle ear fluid and linked to otitis media in children. most patients affected are asymptomatic or experience mild symptoms. various theories explaining the involvement of the ear following covid infection have been pos tulated, which include immune mediated damage,haematogenous spread, ischaemia theory, inflammation of auditory pathway components, presence of angiotensin converting enzyme receptors (ace2) receptors in neurons and glial cell. the hearing loss in covid-19 could also be the consequence of therapy with chloroquine and hydroxychloroquine, which are part of clinical practice guidelines for covid-19 treatment in several countries . these drugs are used for the treatment of malaria and some chronic inflammatory diseases as well. it is well known that these medications can induce hearing loss. ototoxicity of chloroquine and hydroxy- chloroquine is the result of inner ear damage . the recommended dose of these drugs for covid-19 treatment is higher than for malaria; therefore, ototoxic effect could be higher.though many vaccines were intro- duced, the disease has hit second and third waves in many countries, elevating the number of infected individuals getting infected . some studies reported that the covid-19 group had significantly poorerhearing thresholds at high frequencies. in addition, the amplitudes of transient evoked otoacoustic emissions ,in two of thesestudies were significantly lower for the covid-19 group.

Eligibility criteria:
inclusion criteria: * age 18_50 exclusion criteria: 1. history of previous ear symptoms, tympanic membrane perforations,ear trauma or ear surgeries 2. evidence of systemic illness as diabetes mellitus, renal disease, patients received ototoxic drugs. 3. evidence of neurologicl or psychiatric disease. 4. covid 19 patients not maintaining saturation and requiring o2 support and intensive care unit patient.
shared decision-making and antimicrobial stewardship in secondary care

Conditions: Antibiotic Prescribing is the Study Focus (no Condition)

Summary: to identify opportunities for antibiotic prescribing shared decision making between patients and prescribers in secondary care.

this is a qualitative study with patients and clinicians in secondary care. we will use semi-structured interviews with patients and clinicians to address the research question. patients that have received antibiotics during a recent inpatient stay will be identified using the hospital electronic prescribing system and a letter inviting study participation will be included in their discharge medication pack. senior prescribing decision makers will be recruited from participating hospitals. in total, we hope to carry out up to 50 interviews with patients and clinicians.

Eligibility criteria:
inclusion criteria: for clinicians: * participant is willing and able to give informed consent for participation in the study. * senior registrar or consultant medical or surgical doctor working at participating hospitals and caring for inpatients. * fluent in english. for patients: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 16 years or above (no upper age limit). * good standard of speaking english and able to read and understand study materials. * received antibiotic for treatment of suspected or confirmed bacterial infection during inpatient stay. exclusion criteria: * for clinicians: * prescribers not currently caring for inpatients for patients: • patient who received prophylaxis antibiotics only
evaluation of atacand® (candesartan) in daily medical practice

Conditions: Hypertension

Summary: this open label, non-interventional study is to show the efficacy of antihypertensive treatment with atacand in hypertensive patients. efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.


Eligibility criteria:
inclusion criteria: * a patient with arterial hypertension who has been prescribed atacand according to physician's judgement, irrespective of the inclusion in the study exclusion criteria: * hypersensitivity to candesartan or any other ingredient of atacand * liver function impairment and/or cholestasis * severe renal insufficiency * woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Keywords: hypertension blood pressure atacand® candesartan
bleeding and blood transfusion in mvr

Conditions: Mitral Valve Disease

Summary: to identify the best approach for mitral valve replacement to decrease risk of bleeding and restrict blood transfusion and its complication.

mitral valve disease is the most common form of the valvular heart disorders including mitral regurgitation and mitral stenosis. surgical treatment includes repair and replacement with different approaches as conventional median sternotomy or minimally invasive approaches. since minimally invasive mitral valve surgery (mmvs) was first described in the mid-to-late 1990s by pioneer surgeons alain carpentier and randolph chitwood, the techniques have evolved to include mini-thoracotomy, port-access thoracoscopic, partial sternotomy, and robotic. right lateral mini-thoracotomy has become the standard approach for mitral valve surgery in many centers. these approaches may result in less surgical trauma, blood transfusions, and pain, thereby leading to a shorter hospital stay and faster return to daily activities. a reduction in postoperative hemorrhage and transfusion requirements have been suggested as a potential advantage of minimally invasive valve surgery. this benefit is important given the significant morbidity and mortality associated with transfusions and re-exploration for bleeding. observational studies suggested that patients undergoing mmvs required fewer units of prbcs transfused per patient and patients were at lower risk of transfusion. rcts did not reach statistical significance. so, more studies were required to reach a definite conclusion. through this study our aim is to evaluate postoperative bleeding and needs for blood transfusion in conventional median sternotomy mitral valve replacement in comparison to minimally invasive approach.

Eligibility criteria:
inclusion criteria: * patients undergoing mitral valve replacement through minimally invasive or median sternotomy at assiut cardiothoracic surgery department. exclusion criteria: * patients refused to be enrolled in research. emergency, redo procedures, active infectious endocarditis, and combined surgery (valve surgery and coronary artery bypass graft).
long-term specified drug use-results survey of betanis tablets

Conditions: Overactive Bladder

Summary: this study is to evaluate the safety and efficacy of long-term use of betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.


Eligibility criteria:
inclusion criteria: * patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.

Keywords: betanis® mirabegron overactive bladder
aztreonam lysine for inhalation in patients with cystic fibrosis and pseudomonas aeruginosa airway infection

Conditions: Cystic Fibrosis; Pseudomonas Aeruginosa Airway Infection

Summary: the primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (azli) 75 mg prior to its commercial availability to patients with cystic fibrosis (cf) and chronic p. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.


Eligibility criteria:
inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for participation in this study: * ≥ 6 years of age * subject has cf as diagnosed by one of the following: * documented sweat chloride ≥ 60 meq/l by quantitative pilocarpine iontophoresis test * two well characterized genetic mutations in the cftr gene * abnormal nasal potential difference with accompanying symptoms characteristic of cf * at high risk for disease progression as defined by one of the following subject populations: * first cohort criteria: * those who are wait listed or eligible for lung transplant based on fev1 criteria. patients who have a level of lung function impairment consistent with lung transplantation criteria, but who are ineligible for transplantation for other reasons, can enroll in this program; or * completed participation in cp-ai-006 (through visit 20). subjects who withdraw from cp-ai-006 prior to completing all courses of azli and all study visits will not be eligible for this protocol. * second cohort criteria: * meets first cohort criteria * fev1 ≤ 40% predicted at the time of consent * third cohort criteria: * meets first or second cohort criteria * fev1 ≤ 50% predicted at the time of consent exclusion criteria: subjects who meet any of the following exclusion criteria are not to be enrolled in this study: * subjects with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance with the protocol or dosing requirements * subjects with hypersensitivity to any of the components of the drug product * currently enrolled in another clinical trial * pregnant or lactating females

Keywords: cystic fibrosis pseudomonas aeruginosa airway infection aztreonam lysine for inhalation
effect of nasal positive airway pressure versus standard care on oxygenation and ventilation during propofol-based sedation for colonoscopy in patients with high risk of airway obstruction

Conditions: Obstructive Sleep Apnea, Obesity

Summary: the purpose of this study is to to compare oxygenation and ventilation on spontaneously ventilating obese patients or those with diagnosed or undiagnosed obstructive sleep apnea (osa) undergoing day colonoscopy under propofol based sedation, between the superno2va et™ nasal positive airway pressure (pap) device and routine care with face mask for oxygen (o2).


Eligibility criteria:
inclusion criteria: * patients undergoing colonoscopy * american society of anesthesiology (asa) physical status i-iii * bmi ≥30 kg/m2 or suspected obstructive sleep apnea exclusion criteria: * inpatient status * active congestive heart failure exacerbation * untreated ischemic heart disease * acute exacerbation of respiratory disorders, including chronic obstructive pulmonary disease (copd) and asthma * emergent procedures * pregnancy * previous enrollment in this study * inability to provide informed consent * additional medical testing planned for the same day * history of allergic reaction to propofol * tracheostomy * supra-glottic or sub-glottic tumor * gastrointestinal tract obstruction or delayed transit (including delayed gastric emptying, gastric bezoar, achalasia, toxic megacolon). * prisoners * unable to fit supernova

Keywords: obstructive sleep apnea total iv anesthesia obesity colonoscopy nasal cpap
effect of acupuncture on mild to moderate active crohn's disease

Conditions: Intestinal Disorder; Inflammatory Bowel Diseases; Crohn Disease

Summary: to observe the clinical effect of acupuncture on crohn's disease (cd) and its influence on brain function activity and the try-kyn metabolism level, and to screen the brain image markers of acupuncture on cd

1. effect of acupuncture on symptoms of cd 2. effect of acupuncture on brain functional activity of cd 3. effect of acupuncture on intestinal and plasma trp-kyn metabolism level of cd 4. screen the brain image markers of acupuncture in the treatment of cd

Eligibility criteria:
inclusion criteria: 1. aged 16-70; 2. patients with mild or moderate active disease (150 ≤ cdai \< 450); 3. patients who are not responsive, intolerant, dependent or refused to use at least mesalazine, glucocorticoid, immunomodulator (azathioprine, methotrexate), anti tnf alpha preparation; 4. patients were not taking medication or were only taking one or more of the following drugs: \[prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or mesalazine (≤4g/d)\] and prednisone was used for at least 1 month, while azathioprine, methotrexate or mesalazine was used for at least 3 months; 5. those who did not use anti-tnf alpha and other agents within 3 months before entering the study; 6. those who have never experienced acupuncture; 7. patients signing informed consent. exclusion criteria: 1. patients who are recently pregnant or in pregnancy or lactation; 2. patients with serious organic diseases; 3. patients diagnosed as psychosis; 4. patients who take antibiotics, probiotics, traditional chinese medicine and other drugs at the same time, or who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial; 5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations; 6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications; 7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year; 8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.

Keywords: acupuncture crohn's disease
a phase 2 study to investigate efficacy and safety of hzn-1116 in participants with sjogren's syndrome

Conditions: Sjogren's Syndrome

Summary: the purpose of this study is to measure the efficacy and safety of hzn-1116 in participants with sjogren's syndrome (ss).

the study will enroll 2 ss populations: population 1 will include participants with moderate to high systemic disease activity; population 2 will include participants with moderate to severe subjective symptoms. this study will include 3 periods: screening (5 weeks), treatment period (48 weeks) and follow-up period (12 weeks). in the treatment period, participants from each of the populations will be randomized to receive subcutaneous (sc) dose of hzn-1116 or placebo. acquired from horizon in 2024.

Eligibility criteria:
key inclusion criteria: * diagnosed with ss by meeting the 2016 american college of rheumatology (acr)/eular classification criteria. * have an essdai score of \>= 5 at screening (only for population 1). * have an esspri score of \>= 5 at screening (only for population 2). * have an essdai score of \< 5 at screening (only for population 2). * positive for anti-ro autoantibodies, rheumatoid factor (rf) at screening, or both at screening. key exclusion criteria: * concomitant system sclerosis. * active malignancy or history of malignancy within the last 5 years with exception of in situ carcinoma of the cervix treated with apparent success with curative therapy \> 12 months prior to screening; or cutaneous basal cell carcinoma following presumed curative therapy. * individuals who are pregnant or lactating or planning to become pregnant during the study. * individuals who have a positive test for, or have been treated for, hepatitis b, hepatitis c, or hiv infection. * individuals with history of more than one episode of herpes zoster and/or opportunistic infections in the last 12 months, with the exception of non-invasive herpes simplex at any site, oral candidiasis, vaginal candidiasis, or cutaneous fungal infections, which are permitted within the prior 12 months unless of unusual severity. individuals with a prior history of ophthalmic herpes zoster will be excluded. * active infections requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring intravenous (iv) antibiotics within 12 months prior to screening. * last administration of experimental biologic or oral agents \< 6 months or 5 half-lives, whichever is longer, before screening. * individuals who have had previous treatment with any biologic b cell-depleting therapy (eg, rituximab, ocrelizumab, inebilizumab, or ofatumumab) within 12 months or other b cell targeting therapy (eg, belimumab) or anti-type i ifn pathway therapy (eg, anifrolumab) \< 6 months before randomization.

Keywords: ss sjogren's hzn-1116 autoimmune disease dry eye syndrome vib1116